[ Price : $8.95]
FDA researchers examine the use of confirmatory evidence with one adequate and well-controlled trial in non-oncologic drug rare di...[ Price : $8.95]
FDA selects former consultant Barclay Butler as its deputy commissioner for operations and chief operating officer.[ Price : $8.95]
Advantage Silver Dental Arrest asks FDA to rescind medical device approvals for silver diamine fluoride and silver fluoride agents...[ Price : $8.95]
Axsome says its solriamfetol met the primary and secondary endpoints in the Phase 3 FOCUS trial in attention deficit hyperactivity...[ Price : $8.95]
CBER director Peter Marks says vaccine clinical trial designs should evaluate the investigational vaccines effect on disease trans...[ Price : $8.95]
FDA grants Powerful Medical a breakthrough device designation for its PMcardio STEMI artificial intelligence electrocardiogram mod...[ Price : $8.95]
FDA approves an Alnylam Pharmaceuticals supplemental NDA for Amvuttra (vutrisiran), an RNAi therapeutic for treating transthyretin...[ Price : $8.95]
FDA approves a Novartis NDA for Fabhalta (iptacopan) for treating adults with C3 glomerulopathy to reduce proteinuria.